Detecting panitumumab/FOLFOX responders in K-Ras wild-type metastatic colorectal cancer through an artificial intelligence-based analytical tool

Background: Patients with K-RAS wild-type (WT) metastatic colorectal cancer (mCRC) are currently considered the optimal candidates for upfront treatment with combinations of chemotherapy and EGFR inhibitors. These combinations significantly extend overall survival (OS) compared to chemotherapy alone. However, a proportion of patients would not achieve this goal. This study has investigated the ability of an…